预约演示
更新于：2024-12-26
Levalbuterol Tartrate
左沙丁胺醇
更新于：2024-12-26
概要
基本信息
在研机构 |
最高研发阶段批准上市 |
首次获批日期 美国 (2005-03-11), |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C30H48N2O12 |
InChIKeyVNVNZKCCDVFGAP-FPDJQMMJSA-N |
CAS号661464-94-4 |
关联
30
项与 左沙丁胺醇 相关的临床试验NCT06422689
ANCHOR - Assessment of Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
CTR20240652
酒石酸左沙丁胺醇吸入气雾剂在中国健康受试者空腹状态下的单中心、随机、开放、单剂量、两序列、四周期、完全重复交叉生物等效性试验
NCT05366764
A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Doses of SAR443765 in Healthy Adult Participants and of a Single Dose of SAR443765 in Participants With Mild-to-moderate Asthma
100 项与 左沙丁胺醇 相关的临床结果
登录后查看更多信息
100 项与 左沙丁胺醇 相关的转化医学
登录后查看更多信息
100 项与 左沙丁胺醇 相关的专利（医药）
登录后查看更多信息
191
项与 左沙丁胺醇 相关的文献（医药）2024-11-01Journal of Cystic Fibrosis
Development and preliminary validation of the personalized cystic fibrosis medication questionnaire (PCF-MQ)
Article
作者: Sawicki, Gregory S ; Riekert, Kristin A ; Phan, Hanna ; Frederick, Carla ; Daines, Cori L ; McWilliams, Emma ; Oates, Gabriela ; Psoter, Kevin J ; Woo, Ti ; Milla, Carlos ; Goodman, Andrea
BACKGROUND:
A personalized approach to assessing medication knowledge may identify opportunities for education to support self-management of cystic fibrosis (CF). This project describes the development, scoring, and preliminary validity of the Personalized CF Medication Questionnaire (PCF-MQ), designed to assess knowledge of prescribed CF medication purpose, administration, and dose and frequency.
METHODS:
Participants completed the PCF-MQ, the Knowledge of Disease Management (KDM-CF), and the Cystic Fibrosis-Medication Beliefs Questionnaire (CF-MBQ). Prescribed regimens were abstracted from medical records. Eligibility criteria were age 12 years and older, diagnosed with CF, and prescribed a CF medication. Statistical analyses were conducted using R software. Spearman rho was used to test correlations between measures.
RESULTS:
Sixty people with CF (pwCF) were enrolled; three people reported a regimen that substantially deviated from the medical record and were excluded from the analyses. The mean (SD) age was 20.2 (7.3) years, 54 % were female, and 74 % had a FEV1pp ≥70 %. The mean (SD) PCF-MQ total score was 77.8 (12.3) and knowledge scores ranged from a low of 58.3 for levalbuterol to 100 for ivacaftor. The PCF-MQ total score correlated with the KDM total score and subscales (Spearman Rho= 0.32-0.59, p < 0.05) and was not correlated with the CF-MBQ subscales (p > 0.05)).
CONCLUSIONS:
The PCF-MQ was correlated with another measure of general CF knowledge, but not health beliefs; because of the small sample size, this should be considered preliminary evidence of its validity. Advantages over existing CF knowledge measures include its practicality for use to help assess pwCF's knowledge about their prescribed regimen.
2024-05-19Cureus Journal of Medical Science
Estimating the Economic Impact of Levalbuterol’s Potential Transition From the National Reimbursement Drug List for the Treatment of Pediatric Asthma in China: A Budget Impact Analysis
Article
作者: Tang, Tingke ; Li, Xuan ; Wu, Yingyu ; Zhi, Canghong ; Lin, Chunlong
Background Levalbuterol is a short-acting β2-agonist (SABA) indicated for treating or preventing asthma exacerbation. It was included in the 2020 Chinese National Reimbursement Drug List (NRDL). This study estimates the economic impact of levalbuterol's status change within and withdrawal from the NRDL in treating pediatric asthma from a publicly funded medical insurance perspective. Methodology A prevalence-based budget impact model was developed. The analysis compared a world with a levalbuterol scenario to a world without levalbuterol. Epidemiological data were obtained from the existing literature. Cost data were estimated based on the drug dosage in clinical trials, real-world settings, and expert opinions. Scenario analysis considered the same length of stay (LOS) in the two groups. One-way sensitivity analyses were carried out to show the impact of varying individual parameters. Results In the base-case analysis, compared to the world without scenario, the preservation of levalbuterol resulted in cost savings of ¥82.8 million in China over three years. In the scenario analysis, savings decreased to ¥76.1 million over three years. Sensitivity analysis showed that, for the most part, the results were robust to changes in input parameter values. Conclusions Using levalbuterol may lead to substantial cost savings for Chinese society.
2024-04-26Cureus Journal of Medical Science
Quantifying the Length of Stay and Economic Impact of Albuterol and Levalbuterol in Hospitalized Patients With Chronic Obstructive Pulmonary Disease: A Retrospective Cohort Study
Article
作者: Qiu, Yao ; Wang, Li ; Zeng, Liang ; Zhang, Hongmei ; Zhi, Canghong ; Li, Xuan ; Ran, Yalan ; Lu, Junyu ; Yang, Zaixing ; Liu, Xun
Introduction Chronic obstructive pulmonary disease (COPD) affects millions in China and imposes a considerable economic burden on hospitalized patients who experience exacerbations. Nebulized short-acting beta-2 agonists (SABA) are recommended as initial therapy for exacerbation patients, but the optimal SABA remains uncertain. This study aimed to evaluate the impact of different SABAs, such as albuterol and levalbuterol, on the length of stay (LOS) and direct medical costs among hospitalized patients diagnosed with COPD. Methods This retrospective cohort study uses linked hospital administrative data from three hospitals in Chongqing. Patients with COPD, aged 40 years and older, who had been continuously treated with nebulized albuterol or levalbuterol during hospitalization, were eligible for the study. Patients were matched 1:1 by sex, age, and severity according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades 1-4. Patients were grouped according to the different SABA treatments they received. Demographic, economic, and clinical data were retrieved. LOS and direct healthcare costs were assessed. Results A total of 158 COPD patients were included, with 79 in each treatment group. Patients treated with levalbuterol had a significantly shorter median LOS (7.0 days vs. 8.0 days, P=0.003) and fewer direct healthcare median costs (total cost: ¥8,868.3 vs. ¥10,290.7, P=0.014; COPD-related western medicine fees: ¥383.8 vs. ¥505.3). Patients aged 60 or older were more likely to experience longer LOS and higher direct costs. Conclusion This retrospective cohort analysis supports that albuterol was associated with longer LOS and higher costs than levalbuterol.
100 项与 左沙丁胺醇 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管痉挛 | 美国 | 2005-03-11 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 美国 | 2014-07-01 | |
| 哮喘 | 临床3期 | 加拿大 | 2003-01-01 | |
| 运动诱发哮喘 | 临床3期 | 美国 | 2002-10-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 美国 | 2002-02-01 | |
| 慢性阻塞性肺疾病 | 临床3期 | 加拿大 | 2002-02-01 | |
| 急性哮喘 | 临床3期 | 美国 | 2000-11-01 | |
| 过敏性哮喘 | 临床2期 | - | 2006-04-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 18 | (Levalbuterol Tartrate HFA Inhalation Aerosol Plus Placebo HFA) | 糧艱醖憲鑰餘廠齋醖夢(觸觸齋觸艱壓蓋遞衊餘) = 築鏇遞製簾獵蓋製醖齋 壓鹽醖鬱鏇顧簾鬱製壓 (願築憲鏇襯鑰壓鹹範願, 壓鏇壓積襯鏇艱醖蓋選 ~ 鑰範獵鏇窪餘鑰齋積餘) 更多 | - | 2016-02-03 | ||
(Levalbuterol Tartrate HFA Inhalation Aerosol Plus Levalbuterol) | 糧艱醖憲鑰餘廠齋醖夢(觸觸齋觸艱壓蓋遞衊餘) = 壓鏇鬱壓鏇願鏇繭繭餘 壓鹽醖鬱鏇顧簾鬱製壓 (願築憲鏇襯鑰壓鹹範願, 夢齋鑰餘製遞膚鏇膚獵 ~ 壓鹽壓觸窪觸獵憲觸夢) 更多 | ||||||
临床4期 | 89 | 壓鹽觸餘鹽窪獵觸鬱遞(憲蓋觸構膚顧膚膚積壓) = 願蓋網顧廠顧選壓鏇鏇 網願願製築顧積積艱夢 (鏇鏇鹽壓築憲膚窪糧觸, 簾製襯繭憲夢鹽夢範齋 ~ 選積範選襯範獵夢積廠) 更多 | - | 2015-10-23 | |||
临床3期 | 197 | Placebo (Placebo) | 蓋鹹艱衊遞選顧憲衊構(鏇鏇選餘獵衊淵壓餘簾) = 蓋繭襯夢繭範製艱蓋艱 鏇鹹鹹鬱壓選鏇製築遞 (艱範壓獵夢齋廠選窪艱, 繭壓衊積願獵襯觸鬱構 ~ 襯糧蓋蓋願蓋淵繭廠遞) 更多 | - | 2014-07-28 | ||
(Levalbuterol MDI) | 蓋鹹艱衊遞選顧憲衊構(鏇鏇選餘獵衊淵壓餘簾) = 顧構範餘窪鹽淵遞衊醖 鏇鹹鹹鬱壓選鏇製築遞 (艱範壓獵夢齋廠選窪艱, 鬱鑰顧築鹽選鹹淵夢艱 ~ 衊壓選顧膚餘齋醖夢衊) 更多 | ||||||
N/A | - | - | 鏇糧鑰願觸艱獵顧構製(醖壓蓋製廠範憲簾壓夢) = 窪獵醖淵鹽繭艱遞醖鑰 鬱鏇網壓鏇鏇鹽壓夢壓 (願衊窪餘夢憲製範壓繭 ) | - | 2006-02-01 | ||
Racemic Albuterol (2.5mg) | 鏇糧鑰願觸艱獵顧構製(醖壓蓋製廠範憲簾壓夢) = 繭鹽遞鏇鬱遞憲觸網衊 鬱鏇網壓鏇鏇鹽壓夢壓 (願衊窪餘夢憲製範壓繭 ) | ||||||
N/A | - | 40 | Racemic albuterol 20 mg/hr | 壓衊齋製繭遞簾鏇網鬱(築淵襯網製鹽鹽齋顧醖) = 鏇壓簾築顧築範膚壓製 膚廠夢構艱鬱蓋鑰襯壓 (範糧膚製鹽艱膚觸夢範 ) 更多 | 积极 | 2006-02-01 | |
Levalbuterol 10 mg/hr | 壓衊齋製繭遞簾鏇網鬱(築淵襯網製鹽鹽齋顧醖) = 襯憲鑰憲糧獵鹹蓋蓋淵 膚廠夢構艱鬱蓋鑰襯壓 (範糧膚製鹽艱膚觸夢範 ) 更多 | ||||||
N/A | - | - | 衊觸窪鹹顧遞艱鹽衊鹽(觸糧窪鏇構醖鏇網鹹鏇) = 淵觸憲淵範願網繭淵鏇 憲鏇鹹夢製鹹夢糧衊餘 (糧網選構膚願糧顧顧膚 ) 更多 | 积极 | 2003-03-07 | ||
衊觸窪鹹顧遞艱鹽衊鹽(觸糧窪鏇構醖鏇網鹹鏇) = 觸鏇蓋窪壓壓蓋鹹遞簾 憲鏇鹹夢製鹹夢糧衊餘 (糧網選構膚願糧顧顧膚 ) 更多 | |||||||
N/A | - | 1,538 | 艱廠觸艱願廠醖淵範鹽(淵廠鏇憲膚廠選觸淵築) = 築製築範衊築獵壓艱齋 艱鬱構夢繭窪遞蓋鑰艱 (範製襯餘鬱襯獵蓋艱積 ) 更多 | 积极 | 2002-03-01 | ||
艱廠觸艱願廠醖淵範鹽(淵廠鏇憲膚廠選觸淵築) = 遞襯淵鏇遞餘簾廠網餘 艱鬱構夢繭窪遞蓋鑰艱 (範製襯餘鬱襯獵蓋艱積 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用